Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264516 | 0.89 | HPGD (0.76) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL12156421 | 0.88 | HPGD (0.80) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL1590985 | 0.88 | HPGD (0.80) | HPGDALDH1A1KDM4ECA12CA1 | |
| Hydrochloric Acid SCHEMBL3562269 | 0.88 | HPGD (0.73) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL4764024 | 0.86 | HPGD (0.69) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL31557878 | 0.84 | HPGD (0.54) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL28022290 | 0.84 | ALDH1A1 (0.59) | HPGDALDH1A1 | |
| SCHEMBL20261717 | 0.82 | CA12 (0.73) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL23840665 | 0.81 | HPGD (0.63) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL25710940 | 0.81 | HPGD (0.68) | HPGDALDH1A1KDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0902018-B1 | 2-(Arylphenyl)amino-imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7141584-B2 | guanidine derivatives containing phenyl and imidazole rings; useful for treating pain conditions from a wide variety of causes such as cancer, trauma, surgery, inflammation etc. | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2004-06-24 | — | — | US | disclosed |
| US-6693200-B2 | IP RECEPTOR ANTAGONISTS; ANTIINFLAMMATORIES AND ANALGESICS | SYNTEX (U.S.A.) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6596876-B2 | Prostaglandin I2 inhibitors | SYNTEX (U.S.A.) LLC | 2003-07-22 | — | — | US | disclosed |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | HPGD 318/4885ALDH1A1 873/4885KDM4E 4214/4885 |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, GRK2, TBXA2R | HPGD 2128/4885ALDH1A1 2564/4885KDM4E 4252/4885 |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, TBXA2R, GRK2 | HPGD 1966/4885ALDH1A1 2682/4885KDM4E 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.